Compass Therapeutics Inc.

2.13
0.06 (2.90%)
At close: Apr 24, 2025, 3:18 PM

Compass Therapeutics Statistics

Share Statistics

Compass Therapeutics has 138.28M shares outstanding. The number of shares has increased by 0.5% in one year.

Shares Outstanding 138.28M
Shares Change (YoY) 0.5%
Shares Change (QoQ) 0.5%
Owned by Institutions (%) 73.67%
Shares Floating 87.84M
Failed to Deliver (FTD) Shares 12.03K
FTD / Avg. Volume 0.74%

Short Selling Information

The latest short interest is 6.62M, so 4.81% of the outstanding shares have been sold short.

Short Interest 6.62M
Short % of Shares Out 4.81%
Short % of Float 6.8%
Short Ratio (days to cover) 6.81

Valuation Ratios

The PE ratio is -4.66 and the forward PE ratio is -4.23. Compass Therapeutics's PEG ratio is 0.82.

PE Ratio -4.66
Forward PE -4.23
PS Ratio 0
Forward PS 0.7
PB Ratio 1.33
P/FCF Ratio -4.88
PEG Ratio 0.82
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Compass Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 19.73, with a Debt / Equity ratio of 0.01.

Current Ratio 19.73
Quick Ratio 19.73
Debt / Equity 0.01
Debt / EBITDA -0.04
Debt / FCF -0.04
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.21M
Employee Count 35
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by 39.19% in the last 52 weeks. The beta is 1.19, so Compass Therapeutics's price volatility has been higher than the market average.

Beta 1.19
52-Week Price Change 39.19%
50-Day Moving Average 2.39
200-Day Moving Average 1.85
Relative Strength Index (RSI) 53.73
Average Volume (20 Days) 1.62M

Income Statement

Revenue n/a
Gross Profit -1.89M
Operating Income -50.36M
Net Income -42.49M
EBITDA -48.47M
EBIT n/a
Earnings Per Share (EPS) -0.33
Full Income Statement

Balance Sheet

The company has 24.23M in cash and 1.73M in debt, giving a net cash position of 22.5M.

Cash & Cash Equivalents 24.23M
Total Debt 1.73M
Net Cash 22.5M
Retained Earnings -315.31M
Total Assets 149.15M
Working Capital 136.71M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -40.62M and capital expenditures -30K, giving a free cash flow of -40.65M.

Operating Cash Flow -40.62M
Capital Expenditures -30K
Free Cash Flow -40.65M
FCF Per Share -0.32
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

CMPX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for CMPX is $8, which is 288.3% higher than the current price. The consensus rating is "Buy".

Price Target $8
Price Target Difference 288.3%
Analyst Consensus Buy
Analyst Count 8
Stock Forecasts

Scores

Altman Z-Score 11.7
Piotroski F-Score 4